ANNOVIS BIO (ANVS) Stock Price, Quote, News and Overview
NYSE:ANVS - New York Stock Exchange, Inc. - US03615A1088 - Common Stock - Currency: USD
ANVS Quote, Performance and Key Statistics
ANNOVIS BIO
NYSE:ANVS (2/3/2025, 5:14:55 PM)
After market: 3.3 +0.06 (+1.85%)3.24
-1.63 (-33.47%)
The current stock price of ANVS is 3.24 USD. In the past month the price decreased by -36.59%. In the past year, price decreased by -70.41%.
ANVS Latest News, Press Releases and Analysis
Top movers in Monday's session
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
Keep an eye on the top gainers and losers in Monday's session.
Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
Traders are paying attention to the gapping stocks in Monday's session.
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering
MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug...
Annovis Bio, Inc. Announces Proposed Public Offering
MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug...
ANVS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.79 | 336.00B | ||
| AMGN | AMGEN INC | 15.03 | 155.28B | ||
| GILD | GILEAD SCIENCES INC | 22.21 | 122.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 922.29 | 121.13B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.68 | 73.28B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.41B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.73B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.80B | ||
| NTRA | NATERA INC | N/A | 23.31B | ||
| BIIB | BIOGEN INC | 8.72 | 20.74B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.57 | 15.83B |
Related stock screener links
About ANVS
Company Profile
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aims to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). The company is headquartered in Malvern, Pennsylvania and currently employs 6 full-time employees. The company went IPO on 2020-01-29. The firm is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.
Company Info
ANNOVIS BIO
101 Lindenwood Drive, Suite 225
Malvern PENNSYLVANIA 19312 US
CEO: Maria Maccecchini
Employees: 11
Company Website: https://www.annovisbio.com/
Investor Relations: https://irpages2.eqs.com/websites/annovis/English/4000/investors-_-media.html
Phone: 14848753192
ANVS FAQ
What is the stock price of ANVS?
The current stock price of ANVS is 3.24 USD.
What is the symbol for ANNOVIS BIO stock?
The exchange symbol of ANNOVIS BIO is ANVS and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is ANVS stock listed?
ANVS stock is listed on the New York Stock Exchange, Inc. exchange.
Is ANVS a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ANVS, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ANVS.
Does ANVS stock pay dividends?
ANVS does not pay a dividend.
What is the Price/Earnings (PE) ratio of ANVS?
ANVS does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.63).
What is the Short Interest ratio of ANVS stock?
The outstanding short interest for ANVS is 14.87% of its float.
ANVS Technical Analysis
ANVS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANVS. ANVS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ANVS Financial Highlights
Over the last trailing twelve months ANVS reported a non-GAAP Earnings per Share(EPS) of -3.63. The EPS decreased by 14.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -285.06% | ||
| ROE | -579.57% | ||
| Debt/Equity | 0 |
ANVS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ANVS. The Buy consensus is the average rating of analysts ratings from 12 analysts.